208 related articles for article (PubMed ID: 17917884)
1. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
3. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
4. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
5. Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody.
Holsti MA; McArthur J; Allison JP; Raulet DH
J Immunol; 1994 Feb; 152(4):1618-28. PubMed ID: 7907103
[TBL] [Abstract][Full Text] [Related]
6. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
7. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
Li Q; Furman SA; Bradford CR; Chang AE
Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+ and CD8+ naïve human T-cells.
Gunnlaugsdottir B; Maggadottir SM; Ludviksson BR
Int Immunol; 2005 Jan; 17(1):35-44. PubMed ID: 15557315
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
[TBL] [Abstract][Full Text] [Related]
10. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naïve CD4+ T cells.
Sung JL; Lin JT; Gorham JD
Int Immunopharmacol; 2003 Feb; 3(2):233-45. PubMed ID: 12586604
[TBL] [Abstract][Full Text] [Related]
11. A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.
Watanabe M; Hara Y; Tanabe K; Toma H; Abe R
Int Immunol; 2005 Mar; 17(3):269-78. PubMed ID: 15668466
[TBL] [Abstract][Full Text] [Related]
12. Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
Moeller M; Kershaw MH; Cameron R; Westwood JA; Trapani JA; Smyth MJ; Darcy PK
Cancer Res; 2007 Dec; 67(23):11428-37. PubMed ID: 18056471
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members.
Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE
J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells.
Lin SJ; Cheng PJ; Hsiao SS
Bone Marrow Transplant; 2006 May; 37(9):881-7. PubMed ID: 16565741
[TBL] [Abstract][Full Text] [Related]
15. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
16. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis.
Zhang X; Nakajima T; Goronzy JJ; Weyand CM
Arthritis Rheum; 2005 Dec; 52(12):3839-49. PubMed ID: 16329093
[TBL] [Abstract][Full Text] [Related]
17. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
[TBL] [Abstract][Full Text] [Related]
18. Notch1 co-localizes with CD4 on activated T cells and Notch signaling is required for IL-10 production.
Benson RA; Adamson K; Corsin-Jimenez M; Marley JV; Wahl KA; Lamb JR; Howie SE
Eur J Immunol; 2005 Mar; 35(3):859-69. PubMed ID: 15688350
[TBL] [Abstract][Full Text] [Related]
19. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells.
Crome SQ; Wang AY; Kang CY; Levings MK
Eur J Immunol; 2009 Jun; 39(6):1480-93. PubMed ID: 19449310
[TBL] [Abstract][Full Text] [Related]
20. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
